Comparison of Immunity Generated by Nucleic Acid-, MF59-, and ISCOM-Formulated Human Immunodeficiency Virus Type 1 Vaccines in Rhesus Macaques: Evidence for Viral Clearance
暂无分享,去创建一个
J. Heeney | D. Fuller | M. van der Kolk | S. Barnett | Yide Sun | B. Morein | P. Mooij | E. Verschoor | P. T. ten Haaft | B. Verstrepen | H. Oostermeijer | Lennart Åkerblom | Mike van der Kolk
[1] K. Überla,et al. A Pathogenic Threshold of Virus Load Defined in Simian Immunodeficiency Virus- or Simian-Human Immunodeficiency Virus-Infected Macaques , 1998, Journal of Virology.
[2] G. Ott,et al. A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2. , 1998, Vaccine.
[3] Dennis R. Burton,et al. Why do we not have an HIV vaccine and how can we make one? , 1998, Nature Medicine.
[4] D. Baltimore,et al. HIV Vaccines—where are we going? , 1998, Nature Medicine.
[5] J. Heeney,et al. The role of type‐1 and type‐2 T‐helper immune responses in HIV‐1 vaccine protection , 1998, Journal of medical primatology.
[6] J. Heeney,et al. A clinically relevant HIV‐1 subunit vaccine protects rhesus macaques from in vivo passaged simian–human immunodeficiency virus infection , 1998, AIDS.
[7] T. Lehner,et al. Targeted lymph‐node immunization with whole inactivated simian immunodeficiency virus (SIV) or envelope and core subunit antigen vaccines does not reliably protect rhesus macaques from vaginal challenge with SIVmac251 , 1998, AIDS.
[8] E. Rosenberg,et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. , 1997, Science.
[9] M. McElrath,et al. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. , 1997, The New England journal of medicine.
[10] C. Cheng‐Mayer,et al. Comparison of in vitro and in vivo infectivity of different clade B HIV-1 envelope chimeric simian/human immunodeficiency viruses in Macaca mulatta. , 1997, Virology.
[11] M. Villacrés-Eriksson,et al. In vivo and in vitro induction of IL-6 by Quillaja saponaria molina triterpenoid formulations. , 1997, Cytokine.
[12] D. Montefiori,et al. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[13] J. Clements,et al. Gene gun‐based nucleic acid immunization alone or in combination with recombinant vaccinia vectors suppresses virus burden in rhesus macaques challenged with a heterologous SIV , 1997, Immunology and cell biology.
[14] J. Haynes,et al. Manipulation of HIV-1 gp120-specific immune responses elicited via gene gun-based DNA immunization. , 1997, Vaccine.
[15] H. Robinson,et al. Nucleic acid vaccines: an overview. , 1997, Vaccine.
[16] K. Steimer,et al. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. , 1997, Vaccine.
[17] K. Steimer,et al. Enhancement of immunodeficiency virus-specific immune responses in DNA-immunized rhesus macaques. , 1997, Vaccine.
[18] A. Prince,et al. Successful nucleic acid based immunization of newborn chimpanzees against hepatitis B virus. , 1997, Vaccine.
[19] D. Weiner,et al. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination , 1997, Nature Medicine.
[20] N. Letvin,et al. HIV-1 env DNA vaccine administered to rhesus monkeys elicits MHC class II-restricted CD4+ T helper cells that secrete IFN-gamma and TNF-alpha. , 1997, Journal of immunology.
[21] A. Sjölander,et al. Iscoms containing purified Quillaja saponins upregulate both Th1-like and Th2-like immune responses. , 1997, Cellular immunology.
[22] R. Webster,et al. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. , 1997, Journal of immunology.
[23] G. Trinchieri,et al. Immunomodulation by Quillaja saponaria adjuvant formulations: in vivo stimulation of interleukin 12 and its effects on the antibody response. , 1997, Cytokine.
[24] G. Nest,et al. MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. , 1996, The Journal of infectious diseases.
[25] R. D. Keys,et al. Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[26] H. Greenberg,et al. Protection against rotavirus infections by DNA vaccination. , 1996, The Journal of infectious diseases.
[27] J. Haynes,et al. Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery , 1996, Journal of virology.
[28] C. Walker,et al. Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[29] J. Sodroski,et al. Utility of SHIV for testing HIV-1 vaccine candidates in macaques. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[30] D. Weiner,et al. In vivo protective anti‐HIV immune responses in non‐human primates through DNA immunization , 1996, Journal of medical primatology.
[31] E. Raz,et al. Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[32] J. Mullins,et al. Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of rhesus monkeys , 1996, Journal of virology.
[33] J. Heeney,et al. Enumeration of lymphokine‐secreting cells as a quantitative measure for cellular immune responses in rhesus macaques , 1995, Journal of medical primatology.
[34] J. Heeney,et al. Protection from HIV-1 envelope-bearing chimeric simian immunodeficiency virus (SHIV) in rhesus macaques infected with attenuated SIV: consequences of challenge. , 1995, AIDS.
[35] J. Mullins,et al. Simian Immunodeficiency Virus DNA Vaccine Trial in Macaques , 1995, Journal of virology.
[36] E. Ido,et al. Construction of human immunodeficiency virus 1/simian immunodeficiency virus strain mac chimeric viruses having vpr and/or nef of different parental origins and their in vitro and in vivo replication. , 1995, The Journal of general virology.
[37] V. Srikantan,et al. Induction of humoral and cellular immune responses to the human immunodeficiency type 1 virus in nonhuman primates by in vivo DNA inoculation. , 1995, Virology.
[38] C. Cheng‐Mayer,et al. Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV). , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[39] G. Nest,et al. Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. , 1994, Journal of immunology.
[40] D. Fuller,et al. A qualitative progression in HIV type 1 glycoprotein 120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine. , 1994, AIDS research and human retroviruses.
[41] A. Osterhaus,et al. Major histocompatibility complex class I-associated vaccine protection from simian immunodeficiency virus-infected peripheral blood cells , 1994, The Journal of experimental medicine.
[42] F. Chiodi,et al. Long-standing protection of macaques against cell-free HIV-2 with a HIV-2 iscom vaccine. , 1994, Journal of acquired immune deficiency syndromes.
[43] J. Ulmer,et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. , 1993, Science.
[44] K. Steimer,et al. Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons , 1992, Journal of virology.
[45] C. Cheng‐Mayer,et al. Host range, replicative, and cytopathic properties of human immunodeficiency virus type 1 are determined by very few amino acid changes in tat and gp120 , 1991, Journal of virology.
[46] K. Steimer,et al. Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120. , 1991, Science.
[47] N. Haigwood,et al. Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells. , 1991, Nucleic acids research.
[48] C. Cheng‐Mayer,et al. Biologic features of HIV-1 that correlate with virulence in the host. , 1988, Science.
[49] R. D. Francis,et al. Some biological and physical properties of molluscum contagiosum virus propagated in cell culture , 1976, Journal of virology.
[50] S. Zolla-Pazner,et al. Immune correlates of protection from HIV infection and AIDS. , 1997, Immunology today.
[51] S. Rowland-Jones,et al. Role of cellular immunity in protection against HIV infection. , 1997, Advances in immunology.
[52] A. Sjölander,et al. Mechanisms behind the immune response induced by immunostimulating complexes. , 1994, AIDS research and human retroviruses.
[53] J. Heeney,et al. HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees. , 1994, Vaccine.
[54] J. Sodroski,et al. Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. , 1992, Journal of acquired immune deficiency syndromes.
[55] A. Osterhaus,et al. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses , 1984, Nature.